The report was prompted by the FDA's 2021 approval of the Alzheimer's disease drug aducanumab (Aduhelm) using the accelerated approval pathway. The aducanumab approval raised concerns in Congress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback